Grant: Idea to Innovation
Dalhousie University
$124,658.00
Phase 1: Development of degradable and multimodal imageable microspheres for transfer to medical device industry
FY 2017-18
Summary
A team of researchers at Dalhousie University have discovered and engineered a new material for use in medical applications. This new material has the potential to provide highly effective, personalized, optimized, and minimally invasive treatment for benign and malignant tumors. The unique features of this material are that (i) it is visible on x-ray and (ii) it dissolves in the human body. Firstly, being visible on x-ray means that while to doctors are placing the material in the patient, they will be able to confirm that they have treated the full tumor, and not just a part of the tumor. Secondly, being degradable means that once the material has treated the tumor it will disappear in the body without harming the patient - allowing repeat treatments for enhanced care. The research team is now requesting funds to (i) demonstrate, in a pre-clinical setting, the critical functional requirements of the material (i.e. ease of use and safety) and (ii) protect the invention by generating engineering specifications that will underpin and strengthen the patent, which protects their invention. It is expected, that if the material passes the key tests funded by this research grant, that the technology would be ready to transfer to a Canadian manufacturing company to produce it for sale on domestic and global markets.
Program
Idea to Innovation
Recipient
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
505848-2017
Name nom
Boyd, Daniel
Department département
Dentistry, Faculty of
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
124658
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Phase 1: Development of degradable and multimodal imageable microspheres for transfer to medical device industry
Keyword
NSERC
Application summary
A team of researchers at Dalhousie University have discovered and engineered a new material for use in medical applications. This new material has the potential to provide highly effective, personalized, optimized, and minimally invasive treatment for benign and malignant tumors. The unique features of this material are that (i) it is visible on x-ray and (ii) it dissolves in the human body. Firstly, being visible on x-ray means that while to doctors are placing the material in the patient, they will be able to confirm that they have treated the full tumor, and not just a part of the tumor. Secondly, being degradable means that once the material has treated the tumor it will disappear in the body without harming the patient - allowing repeat treatments for enhanced care. The research team is now requesting funds to (i) demonstrate, in a pre-clinical setting, the critical functional requirements of the material (i.e. ease of use and safety) and (ii) protect the invention by generating engineering specifications that will underpin and strengthen the patent, which protects their invention. It is expected, that if the material passes the key tests funded by this research grant, that the technology would be ready to transfer to a Canadian manufacturing company to produce it for sale on domestic and global markets.
